Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
Monika D Scuron, Brittany L Fay, Andrew J Connell, Michael T Peel, Paul A Smith, Monika D Scuron, Brittany L Fay, Andrew J Connell, Michael T Peel, Paul A Smith
Abstract
The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs patients' quality of life, with pruritus being a common complaint. The sensation of itch results from the interplay between epidermal barrier dysfunction, upregulated immune signaling and the activation of the central nervous system. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a central role in pro-inflammatory cytokine signaling in AD. Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651). The efficacy of ruxolitinib cream was tested in murine models of acute and chronic dermatitis and was also characterized in an ex vivo human skin dermatitis model. Ruxolitinib cream was highly effective at ameliorating disease symptoms in multiple murine dermatitis models through downregulation of T helper (Th)2-driven inflammation, resulting in reduced skin thickening and decreased itch. Pathway analysis of mouse ear tissue and human skin explants underscored the role for ruxolitinib in ameliorating inflammation and reducing itch via modulation of the JAK-STAT pathway. Together, the data offer a strong rationale for the use of ruxolitinib cream as a potent therapeutic agent for the clinical management of atopic dermatitis.
Keywords: JAK/STAT signaling pathway; dermatitis; inflammation; pruritus; ruxolitinib.
Conflict of interest statement
All authors are employees and shareholders of Incyte Corporation.
Copyright © 2021 Scuron, Fay, Connell, Peel and Smith.
Figures
References
- Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol (2019) 180(3):464–74.
- Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers (2018) 4(1):1.
- Jachiet M, Bieuvelet S, Argoud AL, Vallee M, Zinai S, Lejeune FX, et al. . Sleep disturbance in atopic dermatitis: a case-control study using actigraphy and smartphone-collected questionnaires. Br J Dermatol (2020). 183(3):577–9.
- Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatolog Treat (2020) 31(8):801–09.
- Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol (2017) 47(7):1096–107.
- Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol (2012) 83(9):1136–45.
- Liongue C, Sertori R, Ward AC. Evolution of Cytokine Receptor Signaling. J Immunol (2016) 197(1):11–8.
- Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal (2017) 15(1):23.
- Howell MD, Fitzsimons C, Smith PA. JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. Ann Allergy Asthma Immunol (2018) 120(4):367–75.
- Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol (2019) 10:2342.
- Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. . Type 2 immunity in the skin and lungs. Allergy (2020) 75(7):1582–605.
- Pinto SM, Subbannayya Y, Rex DAB, Raju R, Chatterjee O, Advani J, et al. . A network map of IL-33 signaling pathway. J Cell Commun Signal (2018) 12(3):615–24.
- Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic Effects of IL-33 on CD4(+) T Cell Differentiation and Effector Functions. Front Immunol (2019) 10:522.
- Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol (2017) 8:475.
- Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Front Immunol (2019) 10:364.
- Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. . Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA (2013) 110(34):13921–6.
- Brandt EB, Sivaprasad U. Th2 Cytokines and Atopic Dermatitis. J Clin Cell Immunol (2011) 2(3):110.
- Wilson SR, The L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. . The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell (2013) 155(2):285–95.
- Shi Z, Jiang W, Wang M, Wang X, Li X, Chen X, et al. . Inhibition of JAK/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis. Mol Cell Biochem (2017) 430(1–2):161–9.
- Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol (2018) 78(3 Suppl 1):S53–62.
- Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol (2017) 76(4):736–44.
- Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol (2018) 142(5):1375–90.
- Suga H, Sato S. Novel topical and systemic therapies in atopic dermatitis. Immunol Med (2019) 42(2):84–93.
- Lynde CW, Bergman J, Fiorillo L, Guenther L, Keddy-Grant J, Landells I, et al. . Clinical Insights About Topical Treatment of Mild-to-Moderate Pediatric and Adult Atopic Dermatitis. J Cutan Med Surg (2019) 23(3_suppl):3S–13S.
- Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat (2020) 31(1):33–40.
- Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. . Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol (2016) 175(5):902–11.
- Dhillon S. Delgocitinib: First Approval. Drugs (2020) 80(6):609–15.
- Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME, et al. . Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol (2020) 145(2):572–82.
- Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol (2020) 82(6):1305–13.
- Imai Y, Yasuda K, Nagai M, Kusakabe M, Kubo M, Nakanishi K, et al. . IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils. J Invest Dermatol (2019) 139(10):2185–94 e3.
- Neil JE, Brown MB, Williams AC. Human skin explant model for the investigation of topical therapeutics. Sci Rep (2020) 10(1):21192.
- Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol (2016) 77(6):1125–42.
- Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. . Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood (2020) 135(20):1739–49.
- Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. . Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med (2020) 382(19):1800–10.
- Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. . TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med (2013) 5(170):170ra16.
- Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, et al. . TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database (Oxford) (2014) 2014:bau007.
- Han NR, Oh HA, Nam SY, Moon PD, Kim DW, Kim HM, et al. . TSLP induces mast cell development and aggravates allergic reactions through the activation of MDM2 and STAT6. J Invest Dermatol (2014) 134(10):2521–30.
- Durum SK. IL-7 and TSLP receptors: twisted sisters. Blood (2014) 124(1):4–5.
- Rochman Y, Kashyap M, Robinson GW, Sakamoto K, Gomez-Rodriguez J, Wagner KU, et al. . Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci USA (2010) 107(45):19455–60.
- David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol (2017) 1027:21–37.
- Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest (1999) 103(8):1103–11.
- Sa DC, Festa CN. Inflammasomes and dermatology. Bras Dermatol (2016) 91(5):566–78.
- Abramovits W, Rivas Bejarano JJ, Valdecantos WC. Role of interleukin 1 in atopic dermatitis. Dermatol Clin (2013) 31(3):437–44.
- Chang YS, Chou YT, Lee JH, Lee PL, Dai YS, Sun C, et al. . Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics (2014) 134(2):e397–405.
- Angelhoff C, Askenteg H, Wikner U, Edell-Gustafsson U. “To Cope with Everyday Life, I Need to Sleep” - A Phenomenographic Study Exploring Sleep Loss in Parents of Children with Atopic Dermatitis. J Pediatr Nurs (2018) 43:e59–65.
- Goh J, Ladiges W. Voluntary Wheel Running in Mice. Curr Protoc Mouse Biol (2015) 5(4):283–90.
- Manzanares G, Brito-da-Silva G, Gandra PG. Voluntary wheel running: patterns and physiological effects in mice. Braz J Med Biol Res (2018) 52(1):e7830.
- Li J, Li L, Zuo H, Ke C, Yan B, Wen H, et al. . T-helper type-2 contact hypersensitivity of Balb/c mice aggravated by dibutyl phthalate via long-term dermal exposure. PLoS One (2014) 9(2):e87887.
- Kim BS. Innate lymphoid cells in the skin. J Invest Dermatol (2015) 135(3):673–8.
- Sabat R, Wolk K, Loyal L, Docke WD, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol (2019) 41(3):359–77.
- Klonowska J, Glen J, Nowicki RJ, Trzeciak M. New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic Targets. Int J Mol Sci (2018) 19(10):3086.
- Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci (2019) 96(1):2–7.
- Fukuyama T, Ehling S, Wilzopolski J, Baumer W. Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model. BMC Pharmacol Toxicol (2018) 19(1):37.
- Seltmann J, Roesner LM, von Hesler FW, Wittmann M, Werfel T. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol (2015) 135(6):1659–61.
- Beck IM, Ruckert R, Brandt K, Mueller MS, Sadowski T, Brauer R, et al. . MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses. PLoS One (2008) 3(6):e2343.
Source: PubMed